Hot Features
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKT... Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.51 | 11.0299488678 | 13.69 | 16.1999 | 13.05 | 94997 | 14.94180781 | DR |
| 4 | 9.96 | 190.076335878 | 5.24 | 29.32 | 3.015 | 2344959 | 16.85003866 | DR |
| 12 | 14.986 | 7002.80373832 | 0.214 | 29.32 | 0.120101 | 886188 | 14.78153467 | DR |
| 26 | 14.8605 | 4377.17231222 | 0.3395 | 29.32 | 0.120101 | 828397 | 7.53127552 | DR |
| 52 | 13.96 | 1125.80645161 | 1.24 | 29.32 | 0.120101 | 575002 | 5.54174359 | DR |
| 156 | 15.032 | 8947.61904762 | 0.168 | 29.32 | 0.120101 | 240996 | 4.56555938 | DR |
| 260 | 13.38 | 735.164835165 | 1.82 | 29.32 | 0.120101 | 206858 | 3.40364927 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.